Appropriate use criteria in dermatopathology: Initial recommendations from the American Society of Dermatopathology

[1]  A. Andea,et al.  Review of the medical literature and assessment of current utilization patterns regarding the use of two common fluorescence in situ hybridization assays in the diagnosis of dermatofibrosarcoma protuberans and clear cell sarcoma , 2018, Journal of cutaneous pathology.

[2]  N. Comfere,et al.  Views of dermatopathologists about clonality assays in the diagnosis of cutaneous T‐cell and B‐cell lymphoproliferative disorders , 2018, Journal of cutaneous pathology.

[3]  Jason B. Lee,et al.  Review of the current medical literature and assessment of current utilization patterns regarding human papillomavirus in situ hybridization and immunohistochemistry in dermatopathology , 2017, Journal of cutaneous pathology.

[4]  Jason B. Lee,et al.  Review of the current medical literature and assessment of current utilization patterns regarding mismatch repair protein immunohistochemistry in cutaneous Muir–Torre syndrome‐associated neoplasms , 2017, Journal of cutaneous pathology.

[5]  H. Kimbrell,et al.  Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[6]  C. Cockerell,et al.  The influence of a gene-expression signature on the treatment of diagnostically challenging melanocytic lesions , 2017, Personalized medicine.

[7]  Z. Sápi,et al.  Unusual Signal Patterns of Break-apart FISH Probes Used in the Diagnosis of Soft Tissue Sarcomas , 2017, Pathology & Oncology Research.

[8]  C. Cockerell,et al.  An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi , 2016, Cancer.

[9]  M. Tetzlaff,et al.  Comparison between melanoma gene expression score and fluorescence in situ hybridization for the classification of melanocytic lesions , 2016, Modern Pathology.

[10]  A. John,et al.  Muir-Torre syndrome (MTS): An update and approach to diagnosis and management. , 2016, Journal of the American Academy of Dermatology.

[11]  R. Brook,et al.  Using the Knowledge Base of Health Services Research to Redefine Health Care Systems , 2015, Journal of General Internal Medicine.

[12]  A. Gutin,et al.  Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma , 2015, Journal of cutaneous pathology.

[13]  F. Chibon,et al.  Fluorescence in situ hybridization analysis is a helpful test for the diagnosis of dermatofibrosarcoma protuberans , 2015, Modern Pathology.

[14]  S. Gruber,et al.  Screening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm. , 2014, JAMA dermatology.

[15]  F. Bhaijee,et al.  Muir-Torre syndrome. , 2014, Archives of pathology & laboratory medicine.

[16]  J. Church,et al.  Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer , 2014, The American Journal of Gastroenterology.

[17]  M. Heckman,et al.  A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir–Torre variant of Lynch syndrome , 2014, Genetics in Medicine.

[18]  Eun Hee Lee,et al.  PDGFB rearrangement in dermatofibrosarcoma protuberans: correlation with clinicopathologic characteristics and clinical implications. , 2013, Human Pathology.

[19]  W. Frankel,et al.  Mismatch Repair Protein Deficiency is Common in Sebaceous Neoplasms and Suggests the Importance of Screening for Lynch Syndrome , 2013, The American Journal of dermatopathology.

[20]  G. Martinez,et al.  Teenagers in the United States: sexual activity, contraceptive use, and childbearing, 2006-2010 national survey of family growth. , 2011, Vital and health statistics. Series 23, Data from the National Survey of Family Growth.

[21]  F. Solé,et al.  Molecular diagnosis of dermatofibrosarcoma protuberans: A comparison between reverse transcriptase‐polymerase chain reaction and fluorescence in situ hybridization methodologies , 2011, Genes, chromosomes & cancer.

[22]  R. Pai,et al.  A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas , 2011, Modern Pathology.

[23]  S. Jhanwar,et al.  Fluorescence in situ hybridization as an ancillary method for the distinction of desmoplastic melanomas from sclerosing melanocytic nevi , 2011, Journal of cutaneous pathology.

[24]  K. Busam,et al.  Fluorescence in situ hybridization for distinguishing cellular blue nevi from blue nevus‐like melanoma , 2011, Journal of cutaneous pathology.

[25]  P. Rutkowski,et al.  Advances in Molecular Characterization and Targeted Therapy in Dermatofibrosarcoma Protuberans , 2011, Sarcoma.

[26]  M. van Glabbeke,et al.  Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Guitart,et al.  Distinguishing Epithelioid Blue Nevus From Blue Nevus-like Cutaneous Melanoma Metastasis Using Fluorescence In Situ Hybridization , 2009, The American journal of surgical pathology.

[28]  Nianxiang Zhang,et al.  Overexpression of ZNF342 by juxtaposition with MPO promoter/enhancer in the novel translocation t(17;19)(q23;q13.32) in pediatric acute myeloid leukemia and analysis of ZNF342 expression in leukemia , 2009, Genes, Chromosomes and Cancer.

[29]  J. Fraumeni,et al.  Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms , 2008, Cancer.

[30]  G. Nuovo,et al.  Verruca Vulgaris of the Vulva in Children and Adults: A Nonvenereal Type of Vulvar Wart , 2007, The American journal of surgical pathology.

[31]  Nicola Pimpinelli,et al.  WHO-EORTC classification for cutaneous lymphomas. , 2005, Blood.

[32]  Y. Iwamoto,et al.  Alterations of the p16INK4a/p14ARF pathway in clear cell sarcoma , 2004, Cancer science.

[33]  F. Pedeutour,et al.  Genetics of dermatofibrosarcoma protuberans family of tumors: From ring chromosomes to tyrosine kinase inhibitor treatment , 2003, Genes, chromosomes & cancer.

[34]  William Stafford Noble,et al.  Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  B. Burnand,et al.  The RAND/UCLA Appropriateness Method User's Manual , 2001 .

[36]  R. Marks,et al.  The prevalence of seborrheic keratoses in people aged 15 to 30 years: is the term senile keratosis redundant? , 2000, Archives of dermatology.

[37]  L Goldman,et al.  Expert panel vs decision-analysis recommendations for postdischarge coronary angiography after myocardial infarction. , 1999, JAMA.

[38]  P. Hogendoorn,et al.  Clear cell sarcoma of tendons and aponeuroses (malignant melanoma of soft parts) and cutaneous melanoma: exploring the histogenetic relationship between these two clinicopathological entities , 1998, The Journal of pathology.

[39]  M. Evans,et al.  Common Association of HPV 2 with Anogenital Warts in Prepubertal Children , 1997, Pediatric dermatology.

[40]  J. Dumanski,et al.  Deregulation of the platelet-derived growth factor β-chain gene via fusion with collagen gene COL1A1 in dermatof ibrosarcoma protuberans and giant-cell fibroblastoma , 1997, Nature Genetics.

[41]  R. Schwartz,et al.  The Muir-Torre syndrome: a 25-year retrospect. , 1995, Journal of the American Academy of Dermatology.

[42]  J. Fletcher,et al.  Ring chromosomes in dermatofibrosarcoma protuberans are composed of interspersed sequences from chromosomes 17 and 22. , 1995, The American journal of pathology.

[43]  Md. Mohidul Hasan,et al.  Presence of human papillomavirus dna in condylomata acuminata in children and adolescents , 1993, Pathology.

[44]  G. Nuovo,et al.  Human papillomavirus segregation patterns in genital and nongenital warts in prepubertal children and adults. , 1991, American journal of clinical pathology.

[45]  K. Fleming,et al.  Human papillomaviruses in anogenital warts in children: typing by in situ hybridisation. , 1990, BMJ.

[46]  F. Enzinger,et al.  Malignant melanoma of soft parts: A reassessment of clear cell sarcoma* , 1983, The American journal of surgical pathology.

[47]  W. Logan,et al.  Clear-cell sarcoma of tendons and aponeuroses. , 1978, Oral surgery, oral medicine, and oral pathology.

[48]  F. Enzinger.  Clear‐cell sarcoma of tendons and aponeuroses. An analysis of 21 cases , 1965, Cancer.